Abstract | Voiding dysfunction comprises a variety of disorders, including stress urinary incontinence and overactive bladder, and affects millions of men and women worldwide. Erectile dysfunction (ED) also decreases quality of life for millions of men, as well as for their partners. Advanced age and diabetes are common comorbidities that can exacerbate and negatively impact upon the development of these disorders. Therapies that target the pathophysiology of these conditions to halt progression are not currently available. However, stem cell therapy could fill this therapeutic void. Stem cells can reduce inflammation, prevent fibrosis, promote angiogenesis, recruit endogenous progenitor cells, and differentiate to replace damaged cells. Adult multipotent stem cell therapy, in particular, has shown promise in case reports and preclinical animal studies. Stem cells also have a role in urological tissue engineering for ex vivo construction of bladder wall and urethral tissue (using a patient's own cells) prior to transplantation. More recent studies have focused on bioactive factor secretion and homing of stem cells. In the future, clinicians are likely to utilize allogeneic stem cell sources, intravenous systemic delivery, and ex vivo cell enhancement to treat voiding dysfunction and ED.
Introduction
Voiding and erectile dysfunction (ED) constitute two of the most common, yet challenging, conditions managed by genitourinary specialists. Voiding dysfunction constitutes a wide range of pathologies, including stress urinary incontinence (SUI) and overactive bladder (OAB). 1 Collectively, these conditions affect millions of patients worldwide and have a significant impact on quality of life (QOL). ED also affects millions of men and is associated with substantial reductions in QOL. The pathophysiology of these conditions often involves acute injury (for example, following radical prostatectomy) and is worsened by chronic comorbid conditions, such as diabetes and obesity. 2, 3 To date, few treatments have been developed that target disease progression. 4 Current standard-of-care therapies, such as the sling for SUI and phospho diesterase type 5 inhibitors for ED, tend to focus on symptom relief rather than correcting pathophysiology. Surgical treatment is often indicated for these conditions and frequently involves the placement of a foreign body-such as a midurethral sling or inflatable penile prosthesis-which can lead to infection or erosion. 5, 6 Ideally, treatment would prevent disease progression and restore anatomy with disease-free tissue. Stem cell therapy holds great promise for treating pathophysiology, as well as for urological tissue engineering and regeneration.
Studies into the use of stem cell therapy to treat voiding dysfunction and ED have generally involved either embryonic or adult multipotent stem cells. Although induced pluripotent stem cells (iPSCs) have been studied in the context of treating urologic malignancies, these cells have yet to be investigated for patients with other urological conditions. The use of adult multipotent, rather than embryonic, stem cells circumvents certain issues regarding the ethical use and acquisition of cells, their tumorigenic potential, and the potential rejection of cells by the recipient's immune system. 7, 8 Mesenchymal stem cells (MSCs), a group of adult stem cells that can be obtained from almost every tissue of the body, hold particular promise for the treatment of voiding dysfunction and ED. 9 These cells have great differentiation capabilities and are known to secrete a host of bioactive factors that are beneficial for tissue repair. Furthermore, MSCs, in conjunction with various scaffolds, can be used to regenerate tissues for reconstructive applications.
In this Review, we provide an overview of the use of stem cell therapy for voiding dysfunction and ED. We identify stem cell sources and isolation techniques, and review several potential mechanisms of action. We provide a summary of major clinical studies, as well as preclinical animal studies, that illustrate potential mechanisms and identify opportunities for further investigation. Finally, we acknowledge hurdles in the transition from laboratory research to clinical practice as stem-cell-based therapies and tissue engineering techniques are incorporated into treatment algorithms for patients with these widespread and challenging disorders.
Although embryonic stem cells and iPSCs provide promising avenues for further research, neither have been used to treat voiding dysfunction or ED as yet. Very small embryonic-like stem cells-primitive adult stem cells that mobilize in the peripheral blood after injury or appropriate stimuli to participate in repair-have demon strated potential as a novel source of cell-based therapeutics. However, these cells have yet to be utilized for urologic applications. 21 Although significant progress has been made in terms of characterizing MSCs in vitro, the in vivo characteristics of MSCs remain elusive. Crisan et al. 22 provide evidence to suggest that the location and cell surface marker expression of MSCs is similar to that of pericytes (perivascular cells) and that a subset of pericytes maintains the in vitro differentiation capacity of MSCs. MSCs could thus be a subset of pericytes, which would explain their presence in almost every organ of the body. However, contrary to this finding, other researchers have demonstrated that human BMSCs and ADSCs assume Key points ■ Voiding and erectile dysfunction are progressive disorders that can significantly diminish quality of life; optimizing the timing of therapy initiation is of great importance ■ Conventional stem cell therapy has focused on the ability of cells to differentiate and replace damaged or diseased tissue; however, mounting evidence suggests that stem cells also exert functional benefit by secreting bioactive factors that trigger local and systemic responses to injury ■ For tissue engineering applications, stems cells can be seeded onto scaffolds to facilitate the incorporation of the graft by native tissue ■ Although most clinical trials in the field have focused on autologous cell sources, the use of allogeneic stem cells offers the potential for 'off-the-shelf' treatment with disease-free cells; this approach is already being used in other fields of medicine ■ Further research is needed to better understand the mechanisms by which stem cells exert their therapeutic action; this information could be used to optimize treatment algorithms pericyte-like marker expression and phenotype in hypoxic culture and in vivo under inflammatory conditions. 23 This would suggest that MSCs attain pericyte-like functions when they are required to reduce inflammatory damage and improve vascularity.
Regardless of their exact location within tissues, MSCs retain niche specificity. MSCs from different tissues require different conditions for in vitro differentiation and have differing gene expression profiles. [24] [25] [26] This variance (in terms of potential to differentiate and secrete bioactive factors) suggests that certain types of MSCs might be more appropriate for treating particular disorders.
Stem cell isolation
The procedure for collecting stem cells typically involves at least three stages. 27 The patient first undergoes a biopsy-generally of the quadricep if muscle tissue is required-to harvest the cells. The cells are then transported to a regulated facility, usually off-site, where the stem cells are isolated from other cell types and grown until they reach adequate numbers. The process of ex vivo stem cell expansion, which involves cycles of differentiation and senescence, inherently alters the pathophysiology of the cells. 28, 29 Although repeat cell sorting immediately prior to delivery can filter out nonstem-cell populations, this process is expensive and time-consuming. Therefore, the cells that are ultimately delivered to the patient, generally via local injection, might be a heterogenous combination of stem cells and differentiated cells.
Transplantation
MSCs are known to induce a characteristically weak allogeneic immune response when transplanted from donor to recipient. 30 This response is thought to result from reduced major histocompatibility complex (MHC) class I expression, ablated MHC class II (or costimulatory molecule) expression, and suppression of immune cell function (by direct or indirect methods). Additionally, MSCs have been shown to actively suppress the proliferation of T cells in vitro. 31 MSCs can be easily xenotransplanted into unrelated nonimmunodeficient animals. 27, 28 However, in humans, MSCs are generally cotransplanted with allogeneic haematopoietic stem cell transplants to suppress the immune response of the recipient and prevent complications. 32 In the future, it is feasible that preharvested cells might be suitable for 'offthe-shelf ' allogeneic use, eliminating the need for separate harvest and delivery procedures. Already, allogeneic cells have been successfully used in cardiology clinical trials and in urological single case reports. 33, 34 Given that cells isolated from patients with genetic predispositions to urological conditions (such as voiding dysfunction and ED) could function suboptimally when reimplanted, allogeneic cells could be of particular use for managing patients with genetic risk factors for these conditions. 31, 32, 34 This hypothesis has been supported by several studies that have used preclinical animal models to show the beneficial effects of transplanting allogeneic MSCs into mice that are genetically predisposed to developing muscular dystrophy. 35 Case reports have hinted at the potential role of allogeneic MSCs for treating severe genetic disorders. In one study, Horwitz et al. 36 treated six children with osteogenesis imperfecta (OI) with allogeneic BMSCs and reported a significant increase in growth velocity without significant adverse effects. A similar result was reported by Le Blanc and colleagues, 37 who performed an intrauterine transplant of allogeneic foetal-liver-derived MSCs into a foetus with severe OI. These studies indicate that treating patients with allogeneic MSCs is a viable option that could eliminate the need for staged procedures and benefit patients with genetic predispositions to conditions such as voiding dysfunction or ED.
Homing and delivery route
In contrast to tissue-specific MSCs, such as ADSCs or MDSCs, stem cells that are derived from the bone marrow circulate throughout the bloodstream and migrate to areas of tissue injury and ischaemia-directed via a gradient of cytokines released by damaged tissues. 38 Homing cytokines, such as stromal derived factor-1 (SDF-1), have been shown to improve functional outcomes (by attracting circulating haematopoietic stem cells) when delivered directly to the hearts of rats with ischaemic cardiomyopathy. 39 Within the context of urological research, the effects of homing cytokines on SUI have been studied most commonly in rats with vaginal distension (VD). Woo et al. 40 showed that levels of these cytokines were significantly increased in the urethra and vagina of rats with VD. This observation was supported by findings from Wood and colleagues, 41 who noted that the upregulation of cytokine expression increased with the duration of VD. Vricella et al. 42 reported similar results in obese mice with SUI, suggesting that obesity might also stimulate the secretion of homing cytokines. Cruz et al. 43 used in vivo bioluminescence imaging to demonstrate homing of BMSCs (injected via tail vein) to the pelvic organs of rats in response to VD. Furthermore, Lin et al. 44 showed that systemic injection of ADSCs was as effective as local injection of ADSCs in terms of functional outcomes, such as elastin organization in the urethra.
Dissaranan et al. 45 suggested that the pelvic organs might not be the only sites at which stem cell homing occurs upon simulated childbirth injury. In this study, a significant number of stem cells were also identified in the spleens of rats with VD. The study authors speculated that systemically injected cells might modulate the immune system via the spleen. It has also been established that ADSCs injected into the corpus cavernosum of rats that have undergone cavernous nerve crush migrate to the bone marrow. 46 Injecting umbilical cord blood stem cells (uCBSCs) intracavernosally into men with diabetic ED has been shown to result in improved blood glucose levels, and decreased medication dosages and glycosylated haemoglobin levels. 33 These preclinical and clinical data suggest that MSCs have an important systemic effect that can be exerted even when therapy is delivered locally.
Although local injection of stem cells results in immediate distribution to the affected area, the stem cell homing that accompanies systemic delivery could have its own advantages. For example, it could help to target diseases with lower levels of focal injury and modulate the immune response via splenic localization. If a time gap exists between injury and treatment administration, homing can be impaired because of a lack of ongoing tissue damage and resultant cytokine expression. A similar obstacle has been circumnavigated in cardiology studies. The use of stem cell therapy to increase expression of SDF-1 following a myocardial infarction has a proven benefit in both rats and humans (based on data from a phase I clinical trial). 39, 47 Electrical stimulation has been shown to facilitate stem cell migration in vitro and could, theoretically, be applied to the target organ in vivo to increase the homing effect. [48] [49] [50] Thus, novel techniques could improve homing in patients whose treatment is initiated long after injury has occurred.
Stem cell differentiation
Initially, the efficacy of stem cell therapy was attributed to the differentiation potential of stem cells. MSCs, for example, are defined by their ability to differentiate in vitro into chondroblasts, osteoblasts, and adipocytes. 51 Stem cell therapy in urology has largely focused on the induced differentiation of stem cells into muscle tissue for urethral sphincter regeneration and urothelium tissue for bladder and urethral reconstruction. 52 For example, pretransplantation enhancement of cells by induced differentiation with 5-azacytidin has been investigated. 52, 53 The differentiation of MSCs into urothelium is a somewhat controversial finding given the endodermal lineage of bladder and urethra urothelium. Nevertheless, several investigators have shown that MSCs differentiate into urothelial-like cells under appropriate conditions 54, 55 probably because the renal pelvis and ureter urothelium are derived from mesoderm 56 -and the ex vivo differentiation of stem cells remains a vital step in the use of tissue engineering for reconstructive purposes.
Bioactive effects of stem cells
Recently, a paradigm shift has occurred in stem cell biology to focus attention on the paracrine, autocrine, and growth factor effects of stem cells. 57, 58 MSCs are known to have antiapoptotic, antiscarring, and neovascularization effects, as well as systemic and local immunomodulatory properties, including the inhibition of T-cell and B-cell proliferation. In addition to their role as effector cells, MSCs also activate and direct endogenous stem and progenitor cells to areas of injury by secreting cytokines and chemokines. 59 In support of this finding, many of the functional and histological improvements associated with stem cell therapy have seemed disproportionate to the number of cells that engraft to injured organs. Lin et al. 44 showed that, although only a limited number of ADSCs engrafted into the urethra of rats subjected to VD and ovariectomy, these cells had a profound effect. Dissaranan et al. 45 reported similar results with BMSCs in response to simulated human childbirth injury. A cardiology study illustrated this point by injecting BMSCs into the hamstrings of hamsters with heart failure. 60 Although cells were unable to migrate out of the muscle, they had significant functional and histological benefit to the heart.
The importance of bioactive factors secreted by stem cells unveils the possibility of harnessing these factors in the laboratory and utilizing them as cell-free treatments. These treatments can be produced in vitro and stored as 'off-the-shelf ' therapeutics for immediate delivery without the need for harvest and expansion. Furthermore, they are potentially cell-free, thus eliminating the risk of rejection, immune reaction, and tumorigenic potential. In vitro stem cell enhancement-for example, by genetically modifying cells to enhance production of bioactive factors-is another potential focus for future research.
Stem cell therapy for voiding dysfunction

Stress urinary incontinence
Several studies have demonstrated the short-term safety and efficacy of stem cell therapies for SUI (Table 1) . Carr et al. 61 showed that injecting autologous MDSCs into the urethral sphincters of eight women with SUI resulted in no significant adverse effects and five of the eight women experienced improvement in their symptoms 1 year after treatment. The same group later confirmed the safety of this treatment approach in a larger blinded study and reported significant improvements in the frequency of stress leak episodes, as well as improvements in QOL indicators, 1 year after periurethral injection of autologous MDSCs. 62 Peters et al. 63 presented supportive data to show the safety of autologous MDSC injections in a large, multicentre trial of patients with SUI. Although the study was underpowered to determine the exact efficacy of each treatment dose, the data suggest a general correlation between increasing stem cell dose and benefit to the recipient. However, these clinical studies failed to elucidate the mechanism of action of stem cells, partly because, in humans, we are unable to track the injected cells in vivo and it can be difficult to acquire human tissue for analysis. Thus we rely upon animal models to supplement our understanding of how stem cells might alter the disease process.
Numerous animal models have sought to address the various causes of SUI, including mechanical injury during vaginal childbirth, pudendal nerve injury, external urethral sphincter (EUS) injury, and the effects of hormonal changes, such as those associated with the menopause (Table 2) . [64] [65] [66] [67] Local injections of BMSCs, MDSCs, and ADSCs have all demonstrated therapeutic potential in animal models that have sustained either mechanical, nerve, or EUS injury-improving both functional and anatomical outcomes. 44, 68, 69 However, levels of stem cell viability and engraftment following delivery are uncertain and have been the focus of some debate. A recent study by Corcos et al. 70 reported an association between BMSC differentiation, smooth muscle antigen upregulation, and desmin expression in a rat model of SUI. In an effort to enhance stem cell retention, cells were delivered concomitantly with either poly lacticco-glycolic acid (PLGA), nerve growth factor (administered via controlled release), brain-derived neurotrophic factor, or calcium concentration microdomains, resulting in significant improvements in leak point pressure, muscle mass, and neuronal density compared to delivery of stem cells alone. 71 Coinciding with the general paradigm shift in stem cell biology towards utilizing MSCs as vehicles for the delivery of bioactive factors, some researchers have begun to investigate the in vitro products of these cells. In a rat model of postpartum SUI, we have shown that administering either a systemic injection of BMSCs or a concentrate of the conditioned media (CCM) produced in vitro results in functional and histologic improvements compared to controls. 45 Our data suggest that paracrine secretions have an important role in the recovery process. A key function of stem cells might thus relate to stem cell homing to areas of injury to stimulate the local secretion of bioactive factors. 
Bladder dysfunction
With regards to other forms of voiding dysfunction, such as OAB and detrusor underactivity, preclinical studies of stem cell therapy have also demonstrated success (Table 3) . Nishijima et al. 72 reported that injecting BMSCs into the bladder walls of rats with bladder outlet obstruction (BOO) restored bladder contractility. These investigators also observed the differentiation of cells labelled with green fluorescent protein into smooth muscle tissue. However, the isolation techniques used in this study did not specifically sort for BMSCs, suggesting that other (downstream) muscle progenitor cells, such as satellite cells, could have differentiated into smooth muscle tissue in vivo instead.
Huang et al. 73 showed that injecting ADSCs locally (via the tail vein) into hyperlipidaemic rats with OAB improved bladder function by enhancing angiogenesis and cholinergic innervation. The study authors tracked cells to the bladder and noted that more ADSCs collect within the bladder following local injection compared to systemic injection, although few differentiated into smooth muscle tissue. ADSCs were shown to improve nerve and blood vessel density-overcoming, in part, one of the key challenges associated with tissue engineering. However, it is unclear whether the increased number of neurons results from increased levels of cell survival or regeneration. Woo et al. 74 delivered BMSCs intravenously into mice with BOO and observed evidence of histological and functional improvement. Both of these studies illustrated the ability of stem cells to initiate bladder remodelling after prolonged obstruction, even in cases when only a few stem cells homed, survived, and differentiated into smooth muscle tissue-suggesting the importance of a paracrine mechanism of action. 73, 74 Preclinical animal studies continue to provide the impetus and rationale for performing clinical trials to analyse the efficacy of systemic cell delivery and cellfree CCM delivery. Future research aims include determining the duration of time after injury (or disease onset) that equates to optimal release of homing cytokines and developing innovative methods for upregulating the expression of these cytokines, such as electrical stimulation.
Stem cell therapy for erectile dysfunction
Very few clinical trials have used stem cells to treat ED. One study of note demonstrated that treating patients with type 2 diabetic ED (n = 7) with human uCBSCs via intracavernosal injection resulted in some short-term benefit (over a period of several months). 30 Importantly, no significant adverse effects were observed. Furthermore, a significant glucose-lowering effect was observed in all patients that persisted over several months, resulting in substantial decreases in diabetes medication dose.
Encouragingly, stem cell therapy for ED has also proven successful in preclinical animal models and the results of these studies support the theory that bioactive factors confer an important mechanism of action (Table 4 ). For example, Huang et al. 75 showed that, although numbers of ADSCs injected intra cavernosally into rat penises decreased significantly after 14 days, these cells exerted a functional effect for up to 1 month compared to controls. In a rat model of cavernosal nerve crush, Albersen et al. 76 compared the intra cavernosal injection of whole ADSCs versus ADSC lysate (osmotically ruptured cell contents that are isolated from sediment and insoluble material). Administering either whole ADSCs or cell lysate significantly improved functional outcomes and histology after 4 weeks. Furthermore, no differences were observed between groups treated with cell lysate and whole ADSC. This suggests that ADSCs influenced injury repair through the paracrine-mediated release of bioactive factors that remained present and active in the cell lysate.
Researchers have also attempted to genetically modify stem cells prior to penile injection to specifically target different components of the erection pathway. With the aim of targeting a neural pathway component, Bivalacqua et al. 77 engineered MSCs to express endo thelial nitric oxide synthase, which dilates cavernous smooth muscle tissue and engorges the penis. When injected into rats with age-induced ED (aged 25 months), the modified MSCs were associated with a more rapid improvement in erectile function compared to wild-type MSCs. Qiu et al. 78 attempted to target the vascular pathway component of erectile function by injecting MSCs engineered to express vascular endothelial growth factor (VEGF) into diabetic rats with ED. Although injecting mice with either VEGF-transfected MSCs or wild-type MSCs resulted in functional and histo logical improvement, benefits were more pronounced in the VEGF-transfected MSC group.
However, the safety concerns associated with genetically modifying cells, especially after viral transduction, cannot be ignored when such technology is applied to humans. Clinical trials are being conducted that investigate the effect of intracoronary injection of adenoassociated viral vectors into patients with heart failure. 79 Ultimately, the added benefits of enhanced bioactive factor production must be weighed against the risk of contamination and unanticipated genetic modification.
Stem cell use in urological tissue engineering
The use of tissue engineering in urology has largely focused on the construction of bladder and urethral wall for augmentation (Table 5 ). Popular strategies have utilized free (scaffold-free) grafts from engineered Studies of bladder or urethral reconstruction with free grafts have focused primarily on tissue engineering with urothelial cells or smooth muscle cells. Urothelial cells can be isolated from bladder washings and cultured to produce bioartificial urothelium, which has been used to reconstruct urethral damage, such as strictures. 82, 83 Currently, the multilayer urothelium transplant is generally not stable enough for suturing and handling during the surgical approach, but this obstacle could potentially be overcome in the future with the use of fibrin glue or scaffolds (pending testing in animal models). 84 Scaffolds destined for cell seeding should promote growth and proliferation of either the transplanted or host cells (or both), enabling them to support the structure and function of engineered tissue. In addition, these scaffolds must be biocompatible and should possess the mechanical and physical characteristics required to function properly at the target site. 80 Taking these requirements into account, naturally derived bio materials-such as collagen, fibrin, or acellular tissue matrices-are advantageous compared to most synthetic materials, which often lack adequate cell-binding properties. Naturally derived scaffolds can be modified by molding, extrusion, phase separation techniques, or electro spinning to create an optimal structure and surface (in terms of porosity and polarity) and ratio of surface area to volume. These techniques can also be used to change the degradation (reabsorption) time associated with scaffolds and the degradation products that are released. 85 Studies in bladder tissue engineering In one of the first clinical studies of bladder tissue engineering, Lai et al. 86 demonstrated that transplanting either healthy or diseased bladder tissue could give rise to functional muscle and urothelium tissue in vitro. Atala et al. 87 later reported on the progress of seven patients (aged 4-19 years) with poorly compliant bladders (secondary to myelomeningocele) treated with augmentation cystoplasty using autologous bladder biopsy-derived cells. The authors reported improved bladder function after cystoplasty over a follow-up period of up to 5 years. However, patients were recruited over 3 years and details regarding the surgical implantation technique-including the type of acellular scaffold used and the use of an omental wrap to aid revascularization-were modified as the study progressed. Although this approach enables the incorporation of new techniques, it limits the clinical utility of the study findings. However, contrary to these early findings, research in paediatric patients has indicated that diseased urothelium displays reduced proliferative and differentiation capacity in vitro. 88 Regardless, bladder augmentation and replacement is critical to improve current outcomes for patients requiring partial cystectomy and cystectomy with neo bladder construction for oncologic indications. Given the risk of harvested autologous bladder tissue harbouring microscopic disease, alternative sources of cells, such as allogenic stem cells or autologous stem cells from other organs, should be considered. The optimal scaffold type for bladder tissue engineering remains unknown. Results associated with the use of stem-cell-seeded scaffolds for cystoplasty vary and are probably dependent on the way in which the small intestine submucosa (SIS) scaffold is set up. 89 Chung et al. 90 reconstructed rat bladder with SIS seeded with BMSCs and demonstrated formation of organized urothelium, discrete muscle fascicles, and positive nerve staining. Sharma et al. 91 performed bladder augmentation using MSC-seeded SIS in baboons and reported typical bladder histoarchitecture. Quantitative morphometric analyses revealed muscle-to-collagen ratios of approximately 32% and 52% in animals treated with unseeded and seeded SIS scaffolds, respectively, 10 weeks after augmentation.
Synthetic scaffolds have been utilized to avoid issues such as structure variability and host response that are commonly associated with biological alternatives. Sharma et al. 92 utilized poly(1,8-octanediol-co-citrate; 93 and ADSCs seeded onto synthetic bladder composites also have potential for future use. 94 Studies in urethral tissue engineering Urethral tissue construction for the repair of urethral defects has undergone similar preclinical investigations to bladder construction and has been associated with many of the same challenges. However, urethral defects are generally smaller and more accessible to native cells migrating across unseeded acellular scaffolds. Preclinical animal studies and clinical trials have shown success using different types of bioscaffolds without stem cell seeding. 86, 88 However, it is worth noting that bare scaffolds depend on native tissue for regeneration, which can only migrate distances of up to 0.5 cm. 95 Stem-cell-seeded scaffolds could potentially overcome this limitation. Preclinical studies in rabbits have shown that a tubularized, acellular collagen scaffold seeded with autologous cells from bladder biopsies can be used to repair and regenerate the urethra, generating tissue with a normal histological appearance. 96 Other investigators have also used rabbit models to show that the use of unseeded scaffolds with growth factor supplementation can negatively affect outcomes (resulting from urethral narrowing and dilation) compared to scaffolds alone. 97 These data suggest that enhanced tissue growth per se does not necessarily equate to favourable outcomes. Instead, a critical balance must be gained in a controlled manner.
In a clinical study by Raya-Rivera and colleagues, 98 five boys with posterior urethral defects underwent repair with tubularized collagen and polyglycolic acid scaffolds seeded with autologous cells. All five patients had functional urethras-determined by uroflowmetry, voiding cystourethrogram, and cystoscopy-and were both continent and voiding without difficulty after a median of 71 months follow-up (although one patient required a pubovesical sling after surgery for daytime SUI). However, despite the success of this clinical series, tissue engineering of the urethra remains a significant engineering challenge and further clinical studies are needed to validate these findings. 99 Studies that have considered the longer-term followup of patients implanted with seeded scaffolds have provided some encouraging preliminary safety data regarding the fate of stem cells. 87, 98 However, many of the in vivo studies that have demonstrated functional improvement with delivery of stem cells have also encountered difficulties determining the ultimate fate of these cells. 44, 45, 75 The in vivo effects of stem cells probably extend beyond cell engraftment, differentiation, and retention. Potential tumorigenesis remains a common concern and, therefore, a potential barrier to widespread clinical adaptation. A shift in focus, from the short-term functional and histological outcomes to the longer-term potential for tumor formation, might help to address this issue.
Conclusions
Although preclinical data and clinical case reports have suggested a potential role for stem cells in the treatment of voiding dysfunction and ED, as well as in urological tissue engineering, more research is needed before stem cells can be fully integrated into clinical practice for urology. The potential role of stem cells in aiding functional recovery in patients with SUI, bladder dysfunction, and ED is incompletely understood. Clinical studies have not yet elucidated mechanisms of action and data from animal models are conflicting. With a few notable exceptions, most studies have established that stem cells do not persist in the target organ for extended periods of time after acute injury. Differentiation is not consistently present during periods of repair. Bioactive factors are thus credited with improvements in functional parameters. Furthermore, it has been suggested that bioactive factors are systemic in nature, which could explain reports of increased homing to the spleen and migration of cells to bone marrow.
Nonetheless, the transplantation of stem cells that have been genetically modified to enhance delivery to the target organ can improve patient outcomes compared to transplantation with unmodified cells, confirming the importance of a localized effect. It seems feasible that the role of stem cells in functional recovery is dependent not only on inherent cellular and regional characteristics, but also on the nature of the pathology. A comprehensive understanding of the mechanism by which stem cells exert benefit should enable researchers to further refine and enhance therapies.
The use of allogeneic stem cell sources could circumvent some of the challenges associated with conventional stem cell therapy, such as the time and expense linked to multiple procedures for cell harvest and delayed delivery. Larger clinical trials of stem cell use in urology have generally utilized autologous stem cell sources whereas trials outside the field have taken advantage of 'off-theshelf ' allogeneic options (with significant success). 34 Despite concerns regarding immune rejection and related adverse reactions, the biology of MSCs-as it is currently understood-suggests that these cells are immune privileged. Thus, immunosuppression (either during or after transplantation) might not always be strictly necessary for allogeneic stem cell therapy. Xenotransplantation of MSCs is standard practice in animal models and small case reports of allogeneic MSC transplantation are surfacing in the published urological literature. 33 Investigators coordinating upcoming clinical trials should consider allogeneic stem cells for treating urological conditions.
In terms of stem cell delivery, homing continues to be investigated as a novel delivery mode, especially for noninvasively targeting disorders that are nonfocal. The major limitation of homing is the delay between injury (for example, caused by vaginal delivery or prostatectomy) and the initiation of treatment, which means that homing signals are often diminished. In order to prevent unnecessary treatment, research is needed to improve the accuracy of predictions regarding disease progression. Alternatively, methods such as electrical stimulation or local injection of homing cytokines could help direct systemically delivered stem cells to the target organ.
Neovascularization and re-innervation of engineered tissues for bladder and urethra reconstruction are critical hurdles to overcome for the application of tissue engineering in urology. Ingrowth of native vessels and nerves-which is stimulated by MSC bioactive factorsis acceptable for smaller grafts. However, full regeneration with functional integration is more challenging. Studies have shown the feasibility of nerve regeneration via the overexpression of neurotrophins, transcription factors, and cytoskeleton-related genes in patients who have sustained peripheral nerve injury. 100 These approaches should be extended to urological practice, potentially in combination with cellular therapy. 101, 102 Animal models are the most promising tools for studying techniques to improve neovascularization and re-innervation.
In summary, stem cell therapies for voiding dysfunction, ED, and urological tissue engineering have shown promise in early trials and these approaches continue to advance. Findings from clinical case reports and larger ongoing clinical trials have supported early evidence from preclinical animal studies. Current challenges include the modification of harvest, isolation, and delivery techniques. In the near future, clinicians could have 'off-the-shelf ' MSCs prepared for single-stage delivery at their disposal, as well as the option to systemically deliver cells and the ability to optimize treatment by selecting niche-specific stem cells for certain pathologies. Ultimately, stem cells could be the next minimally invasive pathophysiology-based therapy for targeting challenging urologic disorders.
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